Isavuconazole, a second-generation broad-spectrum triazole with activity against yeasts, dimorphic fungi, and molds, has a favorable safety profile and predictable pharmacokinetics. Patients typically tolerate isavuconazole well with fewer drug–drug interactions.

Isavuconazole is an triazole antifungal with broad spectrum of activity and good safety profile 1. It is approved by the FDA and EMA for the treatment of invasive aspergillosis and mucormycosis. It works by inhibiting fungal cell membrane synthesis.

Isavuconazonium, sold under the brand name Cresemba, is a systemic antifungal medication of the triazole class which is used to treat invasive aspergillosis and mucormycosis. [9][7][8][12] It is used as the sulfate. [9] . It is taken by mouth or given via injection into a vein. [9]

2023年12月21日 · Cresemba (isavuconazonium sulfate) is an antifungal medication that may be used to treat invasive fungal infections caused by aspergillosis or mucormycosis in adults and children. It is available as a capsule or as an injection for intravenous administration with the following restrictions:

Isavuconazole is a novel broad-spectrum triazole agent. Here we summarize its characteristics and compare it with the currently available antifungal agents. Isavuconazole is administered as a prodrug, and it is water soluble. Oral and intravenous formulations are available.

2020年11月29日 · Isavuconazole, a second-generation broad-spectrum triazole with activity against yeasts, dimorphic fungi, and molds, has a favorable safety profile and predictable pharmacokinetics. Patients typically tolerate isavuconazole well with fewer drug-drug interactions.

Isavuconazonium is approved for the treatment of invasive aspergillosis and mucromycosis when patients are intolerant of alternative antifungal agents (voriconazole for aspergillosis or amphotericin B for mucormycosis).

Isavuconazole is an triazole antifungal with broad spectrum of activity and good safety profile. It is approved by the FDA and EMA for the treatment of invasive aspergillosis and mucormycosis. It works by inhibiting fungal cell membrane synthesis.

Isavuconazole is the newest of the clinically available advanced generation triazole antifungals and is active against a variety of yeasts, molds, and dimorphic fungi. Its current FDA-approved indications include the management of invasive ...

Isavuconazole is a second-generation triazole with activity against a broad spectrum of clinically important fungi. Its water-soluble prodrug, isavuconazonium sulfate (Cresemba ®), available in interchangeable intravenous and oral formulations, is approved in the USA and EU for the treatment of adults with invasive aspergillosis and ...